Plan / Example for Process of Selection of Candidates Throughout the time of our SPORE, we have selected candidates for developmental support from the base of talent that exists between young laboratory and clinical investigators throughout the Johns Hopkins Medical Institutions. Several types of individuals have been sought. First, post-doctoral fellows who were receiving training directly in lung cancer research who have shown exceptional potential for such endeavors, and who are committed to academic careers in this arena, were identified. We also sought individuals, again, at the post-doctoral levels, who were training in other disciplines, but who were developing expertise that could foster exceptional translational research in lung cancer. Second, we identified young junior faculty members who had demonstrated potential in translational lung cancer research, and who were dedicated to including such goals in establishing their first faculty positions. In each case, the funds requested constituted the first national funding for these promising investigators. Finally, we have particularly looked for talented young clinicians who could markedly enhance our capacity to move our most promising work to the highest translational phases, especially if given protected time, through the career development funds, to spend extended time with SPORE work. The decision process for identifying, selecting and approving candidates to receive Career Development funds was outlined in the Program Description, but is repeated here for convenience of the reviewers. The PI and/or members of the SPORE steering committee shown inside the triangle in Figure 1, below, identify all of our awardees. Once all have agreed, we seek consultation from one of the advisory mechanisms depicted outside the triangle in Figure 1 and this always includes the Cancer Center Director, who is, in this interim period, the SPORE PI.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058184-17
Application #
8374595
Study Section
Special Emphasis Panel (ZCA1-GRB-I)
Project Start
Project End
Budget Start
2011-12-01
Budget End
2012-11-30
Support Year
17
Fiscal Year
2012
Total Cost
$66,953
Indirect Cost
$12,694
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Zhong, Yi; Macgregor-Das, Anne M; Saunders, Tyler et al. (2016) Mutant p53 Together with TGFβ Signaling Influence Organ-Specific Hematogenous Colonization Patterns of Pancreatic Cancer. Clin Cancer Res :
Chiappinelli, Katherine B; Zahnow, Cynthia A; Ahuja, Nita et al. (2016) Combining Epigenetic and Immunotherapy to Combat Cancer. Cancer Res 76:1683-9
Sussan, Thomas E; Gajghate, Sachin; Thimmulappa, Rajesh K et al. (2015) Exposure to electronic cigarettes impairs pulmonary anti-bacterial and anti-viral defenses in a mouse model. PLoS One 10:e0116861
Chiappinelli, Katherine B; Strissel, Pamela L; Desrichard, Alexis et al. (2015) Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses. Cell 162:974-86
Belinsky, Steven A (2015) Unmasking the lung cancer epigenome. Annu Rev Physiol 77:453-74
Vendetti, Frank P; Topper, Michael; Huang, Peng et al. (2015) Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung cancer. Oncotarget 6:56-70
Kim, Jung-Hyun; Thimmulappa, Rajesh K; Kumar, Vineet et al. (2014) NRF2-mediated Notch pathway activation enhances hematopoietic reconstitution following myelosuppressive radiation. J Clin Invest 124:730-41
Gardner, Eric E; Connis, Nick; Poirier, John T et al. (2014) Rapamycin rescues ABT-737 efficacy in small cell lung cancer. Cancer Res 74:2846-56
Ahuja, Nita; Easwaran, Hariharan; Baylin, Stephen B (2014) Harnessing the potential of epigenetic therapy to target solid tumors. J Clin Invest 124:56-63
Izumchenko, Evgeny; Chang, Xiaofei; Michailidi, Christina et al. (2014) The TGFβ-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 74:3995-4005

Showing the most recent 10 out of 252 publications